Risk management for prescribing biological therapies-Reference-Cited by-同舟云学术

Risk management for prescribing biological therapies

Published:2016-01 Issue:1 Volume:23 Page:50-67
ISSN:2444-4405
Container-title:Revista Colombiana de Reumatología (English Edition)
language:en
Short-container-title:Revista Colombiana de Reumatología (English Edition)

Author:

Forero Elías,Chalem Monique,Vásquez Gloria,Jauregui Edwin,Medina Luis Fernando,Pinto Peñaranda Luis Fernando,Medina John,Medina Yimy,Jaimes Diego,Arbelaez Ana Milena,Domínguez Aura María,Fernández Andrés,Felipe-Díaz Oscar Jair,Chalem Philippe,Caballero Uribe Carlo Vinicio,Jannaut María José,García Ixhel,Bautista Wilson,Ramírez Figueroa Javier,Cortés Jorge,Quintero Jorge,Rodríguez Nohora

Publisher

Elsevier BV

Reference227 articles.

1. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas;Reino;Reumatol Clin,2011

2. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations;Iannone;J Rheumatol Suppl,2014

3. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection;Dinnes;Health Technol Assess,2007

4. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases for candidates for therapy with tumor necrosis factor alpha inhibitors — March 2008 update;Eurico Fonseca;Rev Port Pneumol,2014

5. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists;Keystone;J Rheumatol,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures;Current Drug Safety;2024-11

2. Frecuencia de positividad de la prueba de intradermorreacción a tuberculina en una cohorte de pacientes con artritis reumatoide;Biomédica;2021-09-22